Linda with the Kalamazoo Kids
Here is a short, simple article on a new cancer treatment
that is raising hope. It involves using
drugs FDA approved for cancer A on cancer B, based on the fact that the cancer-driving
mutations in both are identical. I would
regarded this as an incontestable slam-dunk, but apparently it isn’t. The clinical trial that established this protocal and the drug it features - Keruda - was funded privately. Keruda
will be supplied by Merck at an estimated cost of $156,000/year. The article estimates that 60,000 people in
the U.S. alone are potential patients.
That multiplies out to $6 2/3 billion per year. Got Merck in your portfolio?
This tip came from my trusted research assistants, Joanne
and Dick Ingwall, who are at this moment enjoying their garden on Cape Cod. Thanks, guys.
No comments:
Post a Comment